SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-010487
Filing Date
2019-11-08
Accepted
2019-11-08 06:17:39
Documents
62
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20190930x10q58f888.htm   iXBRL 10-Q 2058218
2 EX-31.1 ex-31d1.htm EX-31.1 14902
3 EX-31.2 ex-31d2.htm EX-31.2 15686
4 EX-32 ex-32.htm EX-32 17734
  Complete submission text file 0001558370-19-010487.txt   6788233

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20190930.xsd EX-101.SCH 44073
6 EX-101.CAL tbph-20190930_cal.xml EX-101.CAL 51740
7 EX-101.DEF tbph-20190930_def.xml EX-101.DEF 166070
8 EX-101.LAB tbph-20190930_lab.xml EX-101.LAB 416298
9 EX-101.PRE tbph-20190930_pre.xml EX-101.PRE 318128
35 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20190930x10q58f888_htm.xml XML 1091588
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 191202000
SIC: 2834 Pharmaceutical Preparations